Results 201 to 210 of about 24,187 (251)

Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis. [PDF]

Heliyon
Bromeo AJ, Karaca I, Ghoraba HH, Lyu X, Than NTT, Ongpalakorn P, Shin YU, Uludag G, Tran ANT, Thng ZX, Do DV, Or CMC, Nguyen QD.   +12 more
europepmc   +1 more source

Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to non-infectious uveitis: a case series of 15 patients. [PDF]

J Ophthalmic Inflamm Infect
Sisk RA, Kiernan DF, Almeida D, Kolomeyer AM, Eichenbaum D, Kitchens JW.   +5 more
europepmc   +1 more source

Correction: Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations. [PDF]

J Ophthalmic Inflamm Infect
Pleyer U, Pavesio C, Miserocchi E, Heinz C, Devonport H, Llorenç V, Burke T, Nogueira V, Kodjikian L, Bodaghi B.   +9 more
europepmc   +1 more source

Lipid profile alterations in non-infectious uveitis: correlation with quantitative optical coherence tomography angiography parameters. [PDF]

BMJ Open Ophthalmol
Shen J, Qin G, Feng L.
europepmc   +1 more source

The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade^®. [PDF]

BMC Med Res Methodol
Weaver J, Voss EA, Cafri G, Beyrau K, Nashleanas M, Suruki R.   +5 more
europepmc   +1 more source

Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations. [PDF]

J Ophthalmic Inflamm Infect
Pleyer U, Pavesio C, Miserocchi E, Heinz C, Devonport H, Llorenç V, Burke T, Nogueira V, Kodjikian L, Bodaghi B.   +9 more
europepmc   +1 more source

Infographic: adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II). [PDF]

Eye (Lond)
Crisostomo KGR, Crisostomo KGR, Azarcon CP, Artiaga JCM.   +3 more
europepmc   +1 more source

Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry. [PDF]

Ophthalmol Ther
Tarsia M, Vitale A, Gaggiano C, Sota J, Maselli A, Bellantonio C, Guerriero S, Dammacco R, La Torre F, Ragab G, Hegazy MT, Fonollosa A, Paroli MP, Del Giudice E, Maggio MC, Cattalini M, Fotis L, Conti G, Mauro A, Civino A, Diomeda F, de-la-Torre A, Cifuentes-González C, Tharwat S, Hernández-Rodríguez J, Gómez-Caverzaschi V, Pelegrín L, Babu K, Gupta V, Minoia F, Ruscitti P, Costi S, Breda L, La Bella S, Conforti A, Mazzei MA, Carreño E, Amin RH, Grosso S, Frediani B, Tosi GM, Balistreri A, Cantarini L, Fabiani C.   +43 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cytokines in Immune-mediated “Non-infectious” Uveitis

Klinische Monatsblätter für Augenheilkunde, 2023
AbstractUveitis is a significant cause of ocular morbidity and accounts for approximately 5 – 10% of visual impairments worldwide, particularly among the working-age population. Infections are the cause of ~ 50% cases of uveitis, but it has been suggested that infection might also be implicated in the pathogenesis of immune-mediated “non-infectious ...
Dimitrios Kalogeropoulos, Panagiotis Kanavaros, Georgios Vartholomatos, George Moussa, Soon Wai Chʼng, Chris Kalogeropoulos   +5 more
openaire   +2 more sources

Non-Infectious Pediatric Uveitis

Pediatric Drugs, 2009
Pediatric non-infectious uveitis remains a rare but potentially sight-threatening group of diseases. However, early screening and treatment can improve outcomes. No single agent has proven to be efficacious in all cases. A wide variety of long-term immunomodulatory treatments are available; these agents differ in both their potency and side effect ...
Sharma, Srilakshmi M, Dick, Andrew D, Ramanan, Athimalaipet V   +2 more
openaire   +3 more sources